Drug Interactions between azithromycin and Jakafi
This report displays the potential drug interactions for the following 2 drugs:
- azithromycin
- Jakafi (ruxolitinib)
Interactions between your drugs
No interactions were found between azithromycin and Jakafi. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
azithromycin
A total of 373 drugs are known to interact with azithromycin.
- Azithromycin is in the drug class macrolides.
-
Azithromycin is used to treat the following conditions:
- Babesiosis
- Bacterial Endocarditis Prevention
- Bacterial Infection
- Bartonellosis
- Bronchitis
- Cervicitis
- Chancroid
- Chlamydia Infection
- COPD, Acute
- Cystic Fibrosis
- Gonococcal Infection, Uncomplicated
- Granuloma Inguinale
- Legionella Pneumonia
- Lyme Disease, Erythema Chronicum Migrans
- Middle Ear Infections
- Mycobacterium avium-intracellulare, Prophylaxis
- Mycobacterium avium-intracellulare, Treatment
- Mycoplasma Pneumonia
- Nongonococcal Urethritis
- Pelvic Inflammatory Disease
- Pertussis
- Pertussis Prophylaxis
- Pharyngitis
- Pneumonia
- Sinusitis
- Skin and Structure Infection
- Skin or Soft Tissue Infection
- STD Prophylaxis
- Tonsillitis/Pharyngitis
- Toxoplasmosis
- Typhoid Fever
- Upper Respiratory Tract Infection
Jakafi
A total of 508 drugs are known to interact with Jakafi.
- Jakafi is in the drug class multikinase inhibitors.
- Jakafi is used to treat the following conditions:
Drug and food interactions
ruxolitinib food
Applies to: Jakafi (ruxolitinib)
GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of ruxolitinib. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.
MANAGEMENT: Patients treated with ruxolitinib should avoid consumption of grapefruit, grapefruit juice, and any supplement containing grapefruit extract. Ruxolitinib may be administered with or without food.
References (1)
- (2011) "Product Information. Jakafi (ruxolitinib)." Incyte Corporation
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Report options
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.